SELLAS Life Sciences Group, Inc. Overview
Pro stress-test →SELLAS is a late-stage clinical biopharmaceutical company focused on development of novel therapies for a broad range of cancer indications. The company is pursuing two lead programs: galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Strategic Profile
Pro stress-test →SELLAS is positioned at a critical inflection point with its pivotal Phase 3 REGAL trial for GPS nearing completion. As of May 11, 2026, 78 of the pre-specified 80 events required to trigger the final analysis had occurred, signaling that topline results were imminent, and the CEO indicated survival times appeared "longer than expected." The company has secured strong cash reserves and is advancing a complementary pipeline with a newly diagnosed and frontline AML study of SLS009 anticipated to begin in the first quarter of 2026.
Competitive Landscape
Pro stress-test →SELLAS competes in the oncology drug development space, focusing on acute myeloid leukemia and other hematologic cancers where current standards of care provide limited survival benefit, positioning itself through science-driven approaches and partnerships with leading research institutions. The company operates in a competitive field with other clinical-stage cancer immunotherapy developers.
Industry Context
SELLAS Life Sciences Group, Inc. operates in Biopharmaceutical/Oncology.
Key facts
Founded: 2012 · Headquarters: New York, US · Employees: 13 · Market cap: $910M